A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs GRF-6019 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Alkahest
- 13 Jun 2019 Planned End Date changed from 1 Nov 2019 to 1 Mar 2020.
- 13 Jun 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Mar 2020.
- 18 Mar 2019 According Alkahest media release, first patient has been dosed in this trial and results are expected in the second half of 2020.